Lantheus Holdings, Inc. (LNTH) Financial Statements
Industry: In Vitro & In Vivo Diagnostic Substances
In fiscal 2025, Lantheus reported revenue of $1.54B, up 0.5% from $1.53B the year before. Net income was $233.6M (a 15.2% net margin), or $3.41 per diluted share. Gross margin was 61.1% and operating margin was 20.2%. Operating activities generated $390.1M of cash. At fiscal year end, Lantheus held $2.23B in total assets against $1.14B in total liabilities, including $359.1M of cash and equivalents.
Open the full interactive Lantheus financials → Quarterly statements, key ratios, valuation history and price charts.
Lantheus Key Stats
| Share Price | $100.02 |
|---|---|
| Market Cap | $6.75B |
| P/E Ratio | 29.3 |
| Revenue YoY Growth | +0.5% |
| 52-Week Range | $50.69 – $110.94 |
| Shares Outstanding | 65.2 million (basic, 2026 Q2) |
Lantheus Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $339.4M | $425.2M | $935.1M | $1.30B | $1.53B | $1.54B |
| Cost of Goods Sold | $200.6M | $237.5M | $353.4M | $586.9M | $545.6M | $599.7M |
| Gross Profit | $138.8M | $187.7M | $581.7M | $709.5M | $988.3M | $942.0M |
| Operating Income | -$4.2M | -$60.8M | $36.2M | $364.6M | $457.0M | $310.8M |
| Pre-Tax Income | -$11.5M | -$75.0M | $26.7M | $410.9M | $431.0M | $313.8M |
| Income Tax | $2.0M | -$3.8M | -$1.3M | $84.3M | $118.5M | $80.2M |
| Net Income | -$13.5M | -$71.3M | $28.1M | $326.7M | $312.4M | $233.6M |
| Diluted EPS | -$0.25 | -$1.06 | $0.40 | $4.65 | $4.36 | $3.41 |
Lantheus Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $384.0M | $406.8M | $377.3M | $388.2M |
| Net Income | $27.8M | $54.1M | $118.4M | $75.0M |
| Diluted EPS | $0.41 | $0.79 | $1.80 | $1.11 |
Lantheus Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $79.6M | $98.5M | $415.7M | $713.7M | $912.8M | $359.1M |
| Current Assets | $184.2M | $235.8M | $677.6M | $1.09B | $1.33B | $900.0M |
| Total Assets | $869.8M | $863.8M | $1.32B | $1.65B | $1.98B | $2.23B |
| Current Liabilities | $80.5M | $90.5M | $247.7M | $187.3M | $240.5M | $333.4M |
| Total Long-Term Debt | $218.4M | $174.8M | $558.1M | $562.5M | $566.3M | $569.4M |
| Total Liabilities | $355.6M | $399.3M | $874.1M | $835.3M | $892.3M | $1.14B |
| Shareholders' Equity | $514.2M | $464.4M | $447.1M | $815.9M | $1.09B | $1.09B |
Lantheus Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $16.4M | $53.9M | $281.8M | $305.3M | $544.8M | $390.1M |
| Cash From Investing | -$4.9M | $3.7M | -$276.5M | $5.9M | -$226.0M | -$627.2M |
| Cash From Financing | -$21.9M | -$39.3M | $311.7M | -$13.1M | -$118.5M | -$316.6M |
| Free Cash Flow | $3.9M | $41.8M | $21.8M | $259.9M | — | — |
Figures from Lantheus' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Lantheus financials page for every line item.
Lantheus Company Profile
| Ticker | LNTH |
|---|---|
| Exchange | Nasdaq |
| Industry | In Vitro & In Vivo Diagnostic Substances |
| Headquarters | Bedford, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001521036 |
Frequently Asked Questions
What was Lantheus' revenue in fiscal 2025?
Lantheus (LNTH) reported revenue of $1.54B for fiscal 2025.
What is Lantheus' annual revenue history?
Lantheus' annual revenue by fiscal year: 2020: $339.4M; 2021: $425.2M; 2022: $935.1M; 2023: $1.30B; 2024: $1.53B; 2025: $1.54B.
What was Lantheus' net income in fiscal 2025?
Lantheus reported net income of $233.6M for fiscal 2025.
What was Lantheus' earnings per share (EPS) in fiscal 2025?
Lantheus' diluted EPS was $3.41 for fiscal 2025 (adjusted for any later stock splits).
What was Lantheus' revenue last quarter?
In its most recent reported quarter (2026 Q2), Lantheus reported revenue of $388.2M.
How much debt does Lantheus have?
Lantheus reported $569.4M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Lantheus are outstanding?
Lantheus reported a weighted average of 65.2 million basic shares outstanding in 2026 Q2.
What is Lantheus' market cap?
Based on its latest closing price, Lantheus (LNTH) has a market capitalization of about $6.75B.
When does Lantheus' fiscal year end?
Lantheus' fiscal year end, as registered with the SEC, is December 31.
Where is Lantheus headquartered?
Lantheus lists its business address in Bedford, Massachusetts in its SEC filings.
Lantheus Competitors & Similar Companies
See all 15 In Vitro & In Vivo Diagnostic Substances companies →